UNMC	UNMC University of Nebraska Medical Center 981180 Nebraska Medical Center Omaha NE 68198-1180 www.reglab.org		S Toll Free 1-800-334-0459 Phone (402) 559-6420 FAX (402) 559-9497		MOLECULAR DIAGNOSTICS TEST REQUEST FORM Lab Use Only	
SHADED AREAS FOR PATIENT LAST NAME		D FIRST NAME		MI	Accession #: Date Rec'd:/ # of Slides:	
SSN BILL OFFICE/CLIENT			E	Collection Date// Collection Time AM		
PATIENT INSURANCE ATTACH COPY OF FRONT AND BACK OF INSURANCE CARD AND ATTACH COPY OF FRONT OF DRIVERS LICENSE IF UNABLE TO OBTAIN COPY OF REQUIRED INFORMATION ALL FIELDS BELOW ARE REQUIRED GUARANTOR NAME/DOB (REQUIRED IF PATIENT IS A MINOR)				SE	PHYSICIAN PROVIDER:	
ADDRESS		СІТҮ	STATE Z	IP		
PRIMARY INSURANCE	IT D MEDICARE OUT-PATIENT			□ INSURANCE		
POLICY ID#		GROUP ID#				
INSURANCE COMPANY			PHONE NUMBER			
INSURANCE COMPANY AD	DRESS	CITY	STATE Z	P		
EFFECTIVE DATE	/ /					
DIAGNOSIS / MEDICAL NECESSITY (ENTER ALL THAT APPLIES)						
ICD-9/10 #1 ICD-9/10 #2 ICD-9/ NOTICE: WHEN ORDERING TESTS FOR WHICH MEDICARE REIMBURSEMENT WILL BE SO			9/10 #3 DUGHT PHYSICIAN	S SHOULD ONL	SECONDARY / TERTIARY INS - ATTACH INFORMATION	
ORDER TESTS THAT A	RE MEDICALLY NECESSARY FOR TI S. FOR MORE INFORMATION SEE r	HE DIAGNOSIS OR TREATMEN eglab.org/billingcompliance/	T OF A PATIENT RA	THER THAN FO	ABN ATTACHED PRIOR AUTHORIZATION ATTACHED	
SOURCE:		MOLEC	ULAR DIAC		TESTING	
Pharmacogenomics					FISH Testing - specify indication(s) or gene(s): Indication:	
Abacavir Sensitivity Genotyping (HLA B*5701) HLA Genotyping for Disease Association					Gene:	
Ankylosing Spondylitis (B27); HLA-B Genotype						
	Antiglomerular basement membrane disease (DR15); HLA-DR Genotyping Autoimmune Thyroid Disease (DR3, DR5); HLA-DR Genotyping				Infectious Disease Testing Adenovirus DNA Detection, Qualitative	
	Hepatitis (DR3, DR4); HLA-DR				B Pertussis DNA Detection	
Behcet's disease (B51); HLA-B Genotyping					BK Virus DNA Detection, Quantitation; Plasma or Urine	
 Bird Shot Retinopathy (A29); HLA-A Genotyping Celiac Disease (HLA-DQA1*05, HLA-DQB1*02, and HLA-DQB1*03;02); HLA-DQ Genotyping 					BK Virus DNA Detection, Tissue Qualitative	
Graves Disease (DR3); HLA-DR Genotyping					CMV DNA Detection, Quantitation, Plasma	
	thyroiditis (DR3); HLA-DR Geno	typing			EBV DNA Detection, Qualitative	
HLA-B*27 Syndromes; HLA-B Genotyping Idiopathic Inflammatory Myopathy; HLA-B, DR and DQ Genotyping					EBV DNA Detection, Quantitation, Plasma Enterovirus RNA Detection	
Myelodysplastic syndrome (MDS) (DR15); HLA-DR Genotyping					HBV DNA Detection, Quantitative	
Narcolepsy (DQB1*06:02); HLA-DQ Genotyping					HCV Genotyping	
Pemphigus vulgaris; HLA-B and HLA-DR Genotyping Rheumatoid Arthritis (DR4); HLA-DR Genotyping					HCV RNA Detection, Quantitative Herpes Virus Panel (HSV, CMV, EBV, VZV, HHV-6)	
	ous Erythematosus (DRB1*15:0		enotyping		HHV-6 DNA Detection, Qualitative	
					HHV-8 DNA Detection, Plasma/Other source	
HLA Other Testing Platelet Support (HLA-A&B Antigen Level)					HIV RNA Detection, Quantitation HSV DNA Detection	
					JC Virus DNA Detection	
Red Blood C	ell Genotyping				Norovirus RNA Detection, stool	
Molecular Se	olid Tumor				Parvovirus DNA Detection VZV DNA Detection	
	9T>A (p.V600k, p.V600R, p.V600	DE) mutation				
	ion (29 common mutations)				Molecular Hematology	
KRAS mutation (codons 12, 13, 61) Microsatellite Instability Analysis (MSI)					BCL1 Translocation t(11;14) BCL2 Translocation t(14:18)	
Sarcoma RT-PCR					BCR-ABL t(9;22) (p190, p210) Qualitative for Diagnosis of CML, ALL	
	-PCR					
Ewing Sarco	-PCR ma t(11;22)				BCR-ABL t(9;22) (p 210) Quantitative for CML Therapeutic Monitoring*	
	-PCR ma t(11;22) sarcoma, t(1 or 2;13)				BCR-ABL ((9;22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication	
Rhabdomyos	ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18)				BCR-ABL ((9;22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication IGH Gene Rearrangement by DNA Amplification IGH Gene Rearrangement by Southern Analysis	
Rhabdomyos Synovial Sard Inherited Dis	ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing	200			BCR-ABL (9:22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication GH Gene Rearrangement by DNA Amplification GH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative	
Rhabdomyos Synovial Sard Inherited Dis Alpha-1 Antit	ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing rypsin Mutation (Z and S Mutatio				BCR-ABL (9:22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication GH Gene Rearrangement by DNA Amplification IGH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative NPM1 Mutation	
Rhabdomyos Synovial Sard Inherited Dis Alpha-1 Antit Hemochroma Factor II Muta	PCR ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing rypsin Mutation (Z and S Mutati atosis Mutation (p.C282Y, p.H63 ation (Prothrombin g.20210G>A	D)			BCR-ABL (9:22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication GH Gene Rearrangement by DNA Amplification GH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative	
Rhabdomyos Synovial Sard Inherited Dis Alpha-1 Antit Hemochroma Factor II Muta Factor V Muta	PCR ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing rypsin Mutation (Z and S Mutatio atosis Mutation (p.C282Y, p.H63 ation (Prothrombin g.20210G>A ation (Leiden p.R506Q)	D)			BCR-ABL (19;22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication GH Gene Rearrangement by DNA Amplification GH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative NPM1 Mutation T Cell Receptor Beta Gene Rearrangement by Southern Analysis	
Rhabdomyos Synovial Sard Inherited Dis Alpha-1 Antit Hemochroma Factor II Muta Factor V Muta Factor II/V Muta	PCR ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing rrypsin Mutation (Z and S Mutatio atosis Mutation (p.C282Y, p.H63 ation (Prothrombin g.20210G>A ation (Leiden p.R506Q) utations (Prothrombin g.20210G	D)			BCR-ABL (19;22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication IGH Gene Rearrangement by DNA Amplification IGH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative NPM1 Mutation T Cell Receptor Beta Gene Rearrangement by Southern Analysis T Cell Receptor Gamma Gene Rearrangement by DNA Amplification MPL Mutation	
Rhabdomyos Synovial Sard Inherited Dis Alpha-1 Antit Hemochroma Factor II Muta Factor II/V Mut Factor II/V Mut	PCR ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing rrypsin Mutation (Z and S Mutatio atosis Mutation (p.C282Y, p.H63 ation (Prothrombin g.20210G>A ation (Leiden p.R506Q) utations (Prothrombin g.20210G nd MTHFR Mutations	D)			BCR-ABL t(9;22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication IGH Gene Rearrangement by DNA Amplification IGH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative NPM1 Mutation T Cell Receptor Beta Gene Rearrangement by Southern Analysis T Cell Receptor Gamma Gene Rearrangement by DNA Amplification MPL Mutation T Cell Receptor Gamma Gene Rearrangement by DNA Amplification MPL Mutation *Include recent CBC and differential test results.	
Rhabdomyos Synovial Sard Inherited Dis Alpha-1 Antit Hemochroma Factor II Muta Factor II/V Mut Factor II/V ar MTHFR Muta	PCR ma t(11;22) sarcoma, t(1 or 2;13) coma t(X;18) sease Testing rrypsin Mutation (Z and S Mutatio atosis Mutation (p.C282Y, p.H63 ation (Prothrombin g.20210G>A ation (Leiden p.R506Q) utations (Prothrombin g.20210G	D)			BCR-ABL t(9;22) (p 210) Quantitative for CML Therapeutic Monitoring* FLT3 Internal Tandem Duplication IGH Gene Rearrangement by DNA Amplification IGH Gene Rearrangement by Southern Analysis JAK2 (p.V617F) Mutation, Qualitative NPM1 Mutation T Cell Receptor Beta Gene Rearrangement by Southern Analysis T Cell Receptor Gamma Gene Rearrangement by DNA Amplification MPL Mutation T Cell Receptor Gamma Gene Rearrangement by DNA Amplification MPL Mutation *Include recent CBC and differential test results.	

Testing Supplies

Regional Pathology Services furnishes specimen-collection supplies for use by clients that send tests to us.

Supplies are ordered online at reglab.org/customer-service/supply-orders/ testing supplies and log-on information may be obtained by calling client services Toll Free 800-334-0459 Phone 402-559-6420

Courier Services

Regional Pathology Services offers an extensive courier network, which includes contracted land and air courier services. Contracted land specimen pickup is provided at no charge for specimens tested by Regional Pathology Services or our designated reference laboratories.

To inquire about scheduled stops and after hours courier service, call Client Services Toll Free 800-334-0459 Phone 402-559-6420

If shipping specimens address to: Regional Pathology Services University Of Nebraska Medical Center 668 S 41ST ST MSB3500 OMAHA NE 68105-1180

Transport Instructions:

Specimen Handling/Shipping

To ensure the safety of personnel and the community, proper handling of specimens for shipment is mandatory. Specimens will be rejected if submitted improperly. The shipper is responsible for the proper packaging and shipping of all specimens. Shippers must be trained and certified by their employer to be able to prepare and ship packages containing diagnostic specimens, biological substances and infectious substances. Rules of the various agencies involved may differ, and may change regularly. Specimen must have at least two patient identifiers and be packaged in sealed plastic bags to prevent leakage or contamination. Place accompanying paperwork in the bag pocket, away from the specimen. Practice universal blood and body fluid precautions when handling specimens.

For tests that require scheduling or special arrangements prior to specimen collection, refer to the Online Test Menu at reglab.org for more information.

Questions?

Contact client services at 800-334-0459